Literature DB >> 23174708

Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.

Mindy G Schuster1, Anne Meibohm, Lisa Lloyd, Brian Strom.   

Abstract

OBJECTIVES: To investigate the risk factors and outcomes associated with Candida krusei bloodstream.
METHODS: We performed a case control study of patients with C. krusei bloodstream infection at the University of Pennsylvania from 1982 to 2010. Controls were without candidemia, and matched to cases on duration of hospitalization and underlying disease.
RESULTS: We enrolled 34 cases and 114 matched controls. Most subjects (62%) had hematologic malignancies. In the multivariate model, including a priori the duration of fluconazole use (OR 1.06; 95% CI 1.00, 1.11) and days of neutropenia (OR 1.01; 95% CI 0.98, 1.13), risk factors associated with C. krusei bloodstream infection were splenectomy (OR 11.66; 95% CI 1.04, 130.64), and exposure to antimicrobials with anaerobic activity (OR 5.74; 95% CI 1.76, 18.67). Outcomes of infected patients were poor. Only 32% of case patients survived to hospital discharge, compared to 89% of controls. For 48% death was attributed to C. krusei infection.
CONCLUSIONS: C. krusei bloodstream infection occurs most commonly in neutropenic patients with hematologic malignancy. The association with prior fluconazole exposure is less marked than previously described. Splenectomy and the receipt of antimicrobials with anaerobic activity are significant risk factors. The outcome of infected patients remains poor, despite appropriate antifungal therapy.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23174708     DOI: 10.1016/j.jinf.2012.11.002

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  11 in total

1.  Species Distribution and Antifungal Susceptibility of Invasive Candidiasis: A 2016-2017 Multicenter Surveillance Study in Beijing, China.

Authors:  Li-Na Guo; Shu-Ying Yu; Meng Xiao; Chun-Xia Yang; Chun-Mei Bao; Yan-Hua Yu; Li-Yan Ye; Yang Yang; Ge Zhang; Jie Liu; Guo-Wei Liang; Rong Min; Yu Zhu; Hong Lei; Yu-Lei Liu; Lin-Juan Liu; Yun-Jian Hu; Po-Ren Hsueh; Ying-Chun Xu
Journal:  Infect Drug Resist       Date:  2020-07-20       Impact factor: 4.003

2.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

3.  Epidemiology and prognostic factors of candidemia in cancer patients.

Authors:  Hung-Jen Tang; Wei-Lun Liu; Hsin-Lan Lin; Chih-Cheng Lai
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

4.  Liquid crystal precursor mucoadhesive system as a strategy to improve the prophylactic action of Syngonanthus nitens (Bong.) Ruhland against infection by Candida krusei.

Authors:  Matheus Aparecido dos Santos Ramos; Giovana Calixto; Luciani Gaspar de Toledo; Bruna Vidal Bonifácio; Lourdes Campaner dos Santos; Margarete Teresa Gottardo de Almeida; Marlus Chorilli; Taís Maria Bauab
Journal:  Int J Nanomedicine       Date:  2015-12-16

5.  The risk and clinical outcome of candidemia depending on underlying malignancy.

Authors:  Olivier Lortholary; Charlotte Renaudat; Karine Sitbon; Marie Desnos-Ollivier; Stéphane Bretagne; Françoise Dromer
Journal:  Intensive Care Med       Date:  2017-03-20       Impact factor: 17.440

6.  Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.

Authors:  Bart Jan Kullberg; José Vasquez; Piroon Mootsikapun; Marcio Nucci; José-Artur Paiva; Jorge Garbino; Jean Li Yan; Jalal Aram; Maria Rita Capparella; Umberto Conte; Haran Schlamm; Robert Swanson; Raoul Herbrecht
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

7.  Genetic Differentiation, Diversity, and Drug Susceptibility of Candida krusei.

Authors:  Jie Gong; Meng Xiao; He Wang; Timothy Kudinha; Yu Wang; Fei Zhao; Weiwei Wu; Lihua He; Ying-Chun Xu; Jianzhong Zhang
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

Review 8.  Current Aspects in the Biology, Pathogeny, and Treatment of Candida krusei, a Neglected Fungal Pathogen.

Authors:  Manuela Gómez-Gaviria; Héctor M Mora-Montes
Journal:  Infect Drug Resist       Date:  2020-06-10       Impact factor: 4.003

9.  Creation and Assessment of a Clinical Predictive Calculator and Mortality Associated With Candida krusei Bloodstream Infections.

Authors:  Ryan Kronen; Kevin Hsueh; Charlotte Lin; William G Powderly; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2018-02-09       Impact factor: 3.835

10.  A multicenter retrospective analysis of the antifungal susceptibility patterns of Candida species and the predictive factors of mortality in South Korean patients with candidemia.

Authors:  In Young Jung; Su Jin Jeong; Young Keun Kim; Hyo Youl Kim; Young Goo Song; June Myung Kim; Jun Yong Choi
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.